Dr. Claire Pomeroy Elected as BD Director

FRANKLIN LAKES, N.J., March 24, 2014 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced the election of Dr. Claire Pomeroy to its Board of Directors.

Dr. Pomeroy, 58, is an expert in infectious diseases and a long-time advocate for public health and patients, especially those with HIV/AIDS.  She is currently President of the Albert and Mary Lasker Foundation, a private foundation that seeks to foster the prevention and treatment of disease and disability by honoring excellence in basic and clinical science, and through public education and research advocacy.

"Dr. Pomeroy's passion for public health, research and healthcare policy, along with her breadth and depth of experience, will undoubtedly bring a valuable perspective to the Company," said Vincent A. Forlenza, BD Chairman, Chief Executive Officer and President. "It is an honor to welcome her to the BD Board of Directors as we advance and evolve our strategy and seek to improve healthcare globally." 

Dr. Pomeroy is a member of the Board of Directors of PRIDE Industries and the Sierra Health Foundation, and also serves as a member of the board of governors for the Foundation for Biomedical Research and the board of trustees for Morehouse School of Medicine.  Dr. Pomeroy is also a member-at-large-representative for the AAAS medical sciences section and was inducted into the Institute of Medicine in 2011.

Dr. Pomeroy received her bachelor's and medical degrees from the University of Michigan and earned an MBA from the University of Kentucky. Dr. Pomeroy previously served as chief of infectious diseases and Associate Dean for research and informatics at the University of Kentucky, and as Dean of the University of California, Davis School of Medicine and CEO of the UC Davis Health System.

About BD
BD is a leading medical technology company that partners with customers and stakeholders to address many of the world's most pressing and evolving health needs. Our innovative solutions are focused on improving drug delivery, enhancing the diagnosis of infectious diseases and cancers, supporting the management of diabetes and advancing cellular research. We are nearly 30,000 associates in 50 countries who strive to fulfill our purpose of "Helping all people live healthy lives" by advancing the quality, accessibility, safety and affordability of healthcare around the world. For more information, please visit www.bd.com.

SOURCE BD (Becton, Dickinson and Company)